Navigation Links
Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Date:11/6/2007

CAMBRIDGE, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2007. At September 30, 2007, Idenix's cash, cash equivalents and marketable securities totaled approximately $136.5 million.

For the third quarter ended September 30, 2007, Idenix reported total revenues of $10.9 million, compared with total revenues of $19.6 million in the third quarter of 2006. Total revenues for the third quarter of 2007 consist of reimbursement by Novartis Pharma AG of expenses incurred by Idenix in connection with the development of Tyzeka(R)/Sebivo(R) (telbivudine), valtorcitabine and valopicitabine, Idenix's product and product candidates for the treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV), respectively, and the amortization of the up-front fees received by Idenix in connection with Novartis' license of telbivudine, valtorcitabine and valopicitabine and product sales of Tyzeka/Sebivo. Idenix reported a net loss of $30.5 million, or a loss of $0.54 per basic and diluted share for the third quarter ended September 30, 2007, compared to a net loss of $19.7 million, or a loss of $0.35 per basic and diluted share for the third quarter ended September 30, 2006. Included in the net loss for the third quarter ended September 30, 2007 was a $6.4 million restructuring charge primarily related to severance costs and impairment of certain fixed assets related to the transition of commercialization, development and manufacturing activities for telb
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... BESLER Consulting , a leading provider ... is pleased to announce that it has been named ... Companies. The list represents the most comprehensive look at ... , "It's been an exciting year for our company ... year's Inc. 5000 list,” said Jonathan Besler, BESLER’s President ...
(Date:8/27/2014)... 30 percent of all positive hospital blood culture samples ... reflect the presence of skin germs instead of specific ... samples into the trash, clinicians may be able to ... these tests to treat patients with antibiotics appropriate to ... Stein and Dr. Danny Alon of TAU,s Sackler Faculty ...
(Date:8/27/2014)... 27, 2014 The American Brain ... of the 2014-2016 Basic Research Fellowships and 2014-2015 Discovery ... the ABTA is seeding the field with talented, bright ... understanding of the causes, effects, diagnosis and treatment of ... scientific committee based on the potential to advance the ...
(Date:8/27/2014)... Home Care Assistance of Scottsdale , a ... to announce the next installment in its renowned Healthy ... Suzanne Steinbaum, attending cardiologist and Director of Women’s Heart ... National Spokesperson for the American Heart Association’s Go Red ... surrounding women and heart disease, what heart disease is ...
(Date:8/27/2014)... An experimental drug designed to help regulate the blood,s iron ... of inflammation, according to results from the first human ... Blood , the Journal of the American ... occurs when red blood cells are in short supply or ... body does not get enough oxygen, since there are fewer ...
Breaking Medicine News(10 mins):Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:'Junk' blood tests may offer life-saving information 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Drug represents first potential treatment for common anemia 2
... By Steven Reinberg HealthDay Reporter , MONDAY, Jan. ... with a small increase in the risk of heart attack, ... in Ohio looked at seven trials involving Pradaxa that included ... data from published clinical trials to tease out a pattern ...
... HealthDay Reporter , MONDAY, Jan. 9 (HealthDay News) -- ... new research that finds losing a loved one can increase ... a significant other,s death, heart attack risk was 21 times ... nearly 2,000 heart attack patients. And within the first week ...
... , MONDAY, Jan. 9 (HealthDay News) -- Nicotine patches and ... therapy" -- don,t help many smokers kick the habit ... This conclusion is based on results of several surveys ... who used nicotine replacement therapy (NRT) did not gain any ...
... Randy Dotinga HealthDay Reporter , MONDAY, Jan. 9 ... used by people trying to quit smoking could serve an ... older patients. The research is preliminary and only involved ... While they,re available over the counter, patches may cost several ...
... -- A 2010 outbreak of Legionnaires, disease in Wisconsin ... hospital lobby, according to a study published in the ... , the journal of the Society for Healthcare Epidemiology ... was detected among eight people in southeast Wisconsin, state ...
... (HealthDay News) -- Waiting up to a year to treat ... not harmful, but waiting many years to get blood pressure ... In the study, published online Jan. 9 in the ... University of Chicago suggested that the one-year delay could give ...
Cached Medicine News:Health News:New Blood Thinner Linked to Higher Heart Attack Risk 2Health News:New Blood Thinner Linked to Higher Heart Attack Risk 3Health News:Grief Is a Real Heartbreaker, Study Finds 2Health News:Grief Is a Real Heartbreaker, Study Finds 3Health News:Nicotine Patches, Gums Won't Help Smokers Quit Long-Term: Study 2Health News:Nicotine Patches, Gums Won't Help Smokers Quit Long-Term: Study 3Health News:Could Nicotine Patches Help Stave Off Memory Loss? 2Health News:Could Nicotine Patches Help Stave Off Memory Loss? 3Health News:Legionnaires' disease outbreak linked to hospital's decorative fountain 2Health News:Short Delay in Treating Blood Pressure Safe for Diabetics: Study 2Health News:Short Delay in Treating Blood Pressure Safe for Diabetics: Study 3
(Date:8/27/2014)... 27, 2014 Decision Resources Group finds that ... Memphis health system and hospital sector ... with rivals Methodist Le Bonheur Healthcare and Baptist Memorial ... coordinate patient care. In addition, a national contract recently ... health plan enrollment in the Memphis ...
(Date:8/27/2014)... , August 27, 2014 ... Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental Lasers), Current ... by MarketsandMarkets, the global Dental Equipment Market is expected ... million in 2014, growing at a CAGR of ... 95 market data tables and 61 figures spread ...
(Date:8/27/2014)... By now, if you haven,t heard about the ... planet. The awareness campaign has brought this devastating disease to ... over $88.5 Million (and counting) for ALS. Every day, more ... starting to as well. One such company, Acorn ... who actually works with ALS sufferers and helps to provide ...
Breaking Medicine Technology:Memphis-area Health Systems Turn Attention to Clinical Integration 2Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: